Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The association of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) is thought to be rare, and its optimal treatment is unknown. Of 130 consecutive patients with a diagnosis of PBC, we identified 12 cases (9.2%) of overlap syndrome (10 females, 2 males; median age, 50 years) strictly defined by the presence of at least two of the three recognized biochemical, serological, and histological criteria of each disease. One patient had initially pure PBC and developed AIH characterized by a flare of alanine transaminase (ALT) (1,330 IU/L; N < 35), elevated immunoglobulin G (IgG) (42 g/L; N < 14.0), and presence of anti-smooth muscle antibodies (ASMA) after 20 months of ursodeoxycholic acid (UDCA) therapy. A complete clinical and biochemical remission was achieved under combination of corticosteroids and UDCA. Eleven patients had features of both diseases at presentation: high serum levels of alkaline phosphatase (AP) (median: 280 IU/L; N < 100), ALT (140 IU/L), and IgG (30.8 g/L), presence of mitochondrial antibodies (n = 9) or ASMA (n = 9), florid bile duct lesions (n = 8), and moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (n = 11). UDCA (13-15 mg/kg/d) given alone in 5 patients induced a significant decrease in biochemical cholestasis but not in ALT levels, and liver fibrosis progressed in 3 patients. Corticosteroids given alone in 6 patients induced a significant decrease in ALT, IgG, and AP levels, but none had a biochemical normalization. The patients with persistently abnormal liver tests under either UDCA or corticosteroids received both UDCA and corticosteroids. A further marked biochemical improvement was observed, and all patients became asymptomatic. We conclude that, in patients with PBC: 1) overlap syndrome with AIH is not rare; 2) flares of AIH may occur either spontaneously or under UDCA; and 3) combination of UDCA and corticosteroids is required in most patients to obtain a complete biochemical response. Overlap syndrome may represent an important and unrecognized cause of resistance to UDCA in patients with PBC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The available data suggest that patients who fulfil the Paris criteria for the diagnosis of AIH either at presentation or during the course of their PBC may benefit from additional immunosuppression in the short-and medium-term [160,162,175,176].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [162]
In the citing paper
“A simplified AIH scoring system has more recently been developed, and, when applied to PBC patients, it identified fewer patients meeting probable AIH criteria than the older scoring system did (4% versus 12%).(125)(126)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [126]
In the citing paper
“Criteria have been proposed by the Paris group for ‘true’ PBC/AIH overlap,272 with two out of three of (a) ALT >5 x ULN, (b) IgG >2 x ULN or positive anti-SMA and (c) liver biopsy with ‘moderate or severe periportal or periseptal lymphocytic piecemeal necrosis (interface hepatitis)’ being suggested as diagnostic of overlap in the context of a PBC diagnosis.”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [272]
Citations
Cites
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Bedossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,003
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Self-citationUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455
Calmus, Y., Gane, P., Rouger, P., & Poupon, R. (1990) · Hepatology · doi:10.1002/hep.1840110104 · Cited by 303
Self-citationInvernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M. (1997) · Hepatology · doi:10.1002/hep.510250507 · Cited by 293
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236
Research works printed but not linked: 2
- Shouval, 1979, Chronic active hepatitis with cholestatic features, Am J Gastroenterol, 72, 542
- Nakamura, 1995, Effect of ursodeoxycholic acid (UDCA) on patients with type 1 auto-immune hepatitis [Abstract], Gastroenterology, 107, 958A
Cited by
Items 301–400 of 743
The Role of Autoantibody Testing in Modern Personalized Medicine
Kayser, C., Dutra, L. A., dos Reis-Neto, E. T., Castro, C. H. D. M., Fritzler, M. J., & Andrade, L. E. C. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08918-6 · Cited by 22
Chinese consensus on the diagnosis and management of autoimmune hepatitis (2015)
Chinese Society of Hepatology, C. S. O. G. &. C. S. O. I. D. (2017) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12479 · Cited by 28
Immunopathogenesis of cholestatic autoimmune liver diseases
Medina, J., Jones, E. A., García‐Monzón, C., & Moreno‐Otero, R. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00765.x · Cited by 19
Yoshida, E. M. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i23.3625 · Cited by 19
Olianas, A., Guadalupi, G., Cabras, T., Contini, C., Serrao, S., Iavarone, F., Castagnola, M., Messana, I., Onali, S., Chessa, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020959 · Cited by 19
Montaño‐Loza, A. J., Lalor, E., & Mason, A. L. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/586173 · Cited by 17
“In a series of patients with PBC, approximately 5% fulfill criteria for overlap with autoimmune hepatitis and these patients benefit from corticosteroid treatment to prevent progressive fibrosis (3,4).”
BackgroundDiagnosing clinical subsets of autoimmune liver diseases based on a multivariable model
Zeniya, M., Watanabe, F., Morizane, T., Shibata, M., Maeyama, S., Kage, M., Nakanuma, Y., & Toda, G. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-005-1713-x · Cited by 19
Graham, R. P., Smyrk, T. C., & Zhang, L. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31824b1dff · Cited by 18
“In addition, examples of AIH/PBC overlap have been well described.(5,12) Twelve cases of PBC/AIH overlap were present in our cases of PBC, and 7 of them showed Z2 intraepithelial Langerhans cells per duct; 3 of them were early stage, and the other 4 were late stage.”
BackgroundREVIEW: Overlap Syndromes of Autoimmune Hepatitis: What Is Known So Far
Durazzo, M., Premoli, A., Fagoonee, S., & Pellicano, R. (2003) · Digestive Diseases and Sciences · doi:10.1023/a:1022597210629 · Cited by 18
“Among 130 subjects with PBC, Chazouilleres et al have identified, 12 cases of overlap syndrome (OLS) (9%) (33).”
Primary Biliary Cirrhosis and Hepatitis C Virus Infection
Floreani, A., Baragiotta, A. M., Leone, M. G., Baldo, V., & Naccarato, R. (2003) · The American Journal of Gastroenterology · doi:10.1016/j.amjgastroenterol.2003.08.021 · Cited by 18
Autoimmune disease overlaps and the liver: Two for the price of one?
Mackay, I. R. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02041.x · Cited by 18
Zhang, H., Li, S., Yang, J., Zheng, Y., Wang, J., Lu, W., Zhou, Y., Yin, Q., Zhu, R., & Guo, C. (2015) · Gastroenterology Review · doi:10.5114/pg.2015.51187 · Cited by 17
Montaño‐Loza, A. J., Lytvyak, E., Hirschfield, G. M., Hansen, B. E., Ebadi, M., Berney, T., Toso, C., Magini, G. M., Villamil, A., Nevens, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.010 · Cited by 17
Overlap syndrome of autoimmune chronic liver diseases: MRI findings
Hyslop, W. B., Kierans, A. S., Leonardou, P., Fritchie, K., Darling, J. M., El‐Azzazi, M., & Semelka, R. C. (2010) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22048 · Cited by 17
“For overlap with PBC, patients met two of three criteria that included alkaline phosphatase (AP) at least twice the upper limit of normal, positive antimitochondrial antibodies (AMA), or presence of a florid duct lesion on liver biopsy (6).”
MethodKorkmaz, H., Buğdacı, M. S., Temel, T., Dağlı, M., & Karabağli, P. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2012.11.001 · Cited by 17
Liver biopsy for histological assessment: The case in favor
Alswat, K., Mumtaz, K., & Jafri, W. (2010) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.61245 · Cited by 17
“[3] Diagnosis of overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis (AIH) requires examination of liver histology.[4] Furthermore, in daily clinical practice, the need for LB is clearer in situations where the possibility of co-existing disorders such as steatosis with hepatitis C (HCV) and h…”
BackgroundVariant syndromes of primary biliary cholangitis
Schulz, L., Sebode, M., Weidemann, S. A., & Lohse, A. W. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.003 · Cited by 18
Yan, Y., Xing, X., Wang, Y., Wang, X., Wang, Z., & Yang, L. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i18.2021 · Cited by 17
New insights into autoimmune liver diseases
Kumagi, T., Alswat, K., Hirschfield, G. M., & Heathcote, J. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00366.x · Cited by 18
Zen, Y., Hübscher, S. G., & Nakanuma, Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00009-1 · Cited by 21
Diagnostic and prognostic scoring systems for autoimmune hepatitis : a review
Ducazu, O., Degroote, H., Geerts, A. M., Schouten, J. N. L., Vlierberghe, H. V., & Verhelst, X. (2021) · Acta gastro-enterologica belgica · doi:10.51821/84.3.014 · Cited by 17
“It was concluded that the simplified scoring system could be superior in assessing overlap syndromes (20).”
BackgroundInfluentialThe Inconvenient Truth of Primary Biliary Cholangitis/Autoimmune Hepatitis Overlap Syndrome
Hussain, N., & Trivedi, P. J. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.007 · Cited by 16
González, L., Orrego, M., Ramírez, L., & Vásquez, G. M. (2010) · Lupus · doi:10.1177/0961203310378673 · Cited by 16
Lee, B. T., Wang, Y., Yang, A. H., Han, H. H., Yuan, L., Donovan, J., Kaplowitz, N., Kanel, G. C., Kahn, J. A., & Dara, L. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.11.024 · Cited by 16
“PBC-AIH patients met the Paris Criteria (7).”
Alric, L., Thébault, S., Selves, J., Péron, J., Mejdoubi, S., Fortenfant, F., & Vinel, J. (2007) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(07)89322-5 · Cited by 16
“Some recent studies have suggested a favorable response to UCDA alone [10, 21] or associated with prednisone [5] in patients with OS.”
BackgroundResultInfluentialNon-invasive diagnosis and follow-up of primary biliary cholangitis
Corpechot, C., Heurgué, A., Tanné, F., Potier, P., Hanslik, B., Decraecker, M., de Lédinghen, V., Ganne‐Carrié, N., Bureau, C., & Bourlière, M. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101770 · Cited by 17
Shen, Z.-X., Wu, D., Xia, J., Wang, X., Zheng, X., Huang, Y., Li, B., Meng, Z., Gao, Y., Qian, Z., et al. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i31.4417 · Cited by 18
Autoantibodies in Primary Biliary Cholangitis
Leung, K. K., & Hirschfield, G. M. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.004 · Cited by 17
“upper limit the normal (ULN), (2) elevation of serum IgG levels greater than 2 times ULN or positive anti-smooth muscle antibody (SMA), and (3) moderate-to-severe interface hepatitis on histology.(7,77) Of note, the presence of anti-double stranded DNA (dsDNA)”
BackgroundCoxiella burnetii as a possible cause of autoimmune liver disease: a case report
Kaech, C., Pache, I., Raoult, D., & Greub, G. (2009) · Journal of Medical Case Reports · doi:10.4076/1752-1947-3-8870 · Cited by 15
“Serology shows markers of AIH (ANA, SMA) and of PBC (AMA, anti-M2 antibodies, elevation of total IgM levels) [1,2].”
BackgroundZepeda-Gómez, S., Montaño‐Loza, A. J., Zapata-Colindres, J. C., Paz, F., Olivera-Martinez, M. A., López-Reyes, A. G., Granados, J., & Vargas‐Alarcón, G. (2009) · Immunological Investigations · doi:10.1080/08820130902846282 · Cited by 15
Toward precision medicine in primary biliary cholangitis
Carbone, M., Ronca, V., Bruno, S., Invernizzi, P., & Mells, G. F. (2016) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.05.023 · Cited by 15
Current and promising therapy for primary biliary cholangitis
Gossard, A. A., & Lindor, K. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601701 · Cited by 16
Wang, R., Lin, Q., Lu, Z., Wen, H., Hu, F., You, J., He, Y., Fang, Y., Bian, Z., Hou, Q., et al. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103163 · Cited by 15
Are Gender Differences Important for Autoimmune Liver Diseases?
Floreani, A., Gabbia, D., & Martin, S. D. (2024) · Life · doi:10.3390/life14040500 · Cited by 17
Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead
Chen, Y., Chen, R., Li, H., & Shuai, Z. (2025) · Immunologic Research · doi:10.1007/s12026-025-09622-9 · Cited by 14
Overlap syndromes of autoimmune hepatitis: diagnosis and treatment
Aguilar-Nájera, O., Velasco-Zamora, J. A., & Torre, A. (2015) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2015.07.001 · Cited by 16
Stasi, C., Leoncini, L., Biagini, M. R., Arena, U., Madiai, S., Laffi, G., Marra, F., & Milani, S. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.10.024 · Cited by 16
Autoimmune liver disease - are there spectra that we do not know?
Fallatah, H. I., & Akbar, H. O. (2011) · Comparative Hepatology · doi:10.1186/1476-5926-10-9 · Cited by 15
“Diagnostic scoring criteria for AIH-PBC have been developed [34] and recently a simplified diagnostic score have been suggested [35].”
BackgroundCurrent trends in the diagnosis and treatment of autoimmune hepatitis in Japan
Ohira, H., & Takahashi, A. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00904.x · Cited by 14
The therapeutic effects of Yongdamsagan-tang on autoimmune hepatitis models
Park, J., Kim, H., Lee, I., Kim, K., Kim, Y., Na, Y., Lee, J. H., & Jang, H.-J. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.015 · Cited by 15
Fan, X., Zhu, Y., Men, R., Wen, M., Shen, Y., Lu, C., & Yang, L. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/1965492 · Cited by 16
Aljumah, A. A., Aljarallah, B. M., Albenmousa, A. H., Khathlan, A. A., Alzanbagi, A., Quaiz, M. A., Al‐Judaibi, B., Nabrawi, K. Y., Hamoudi, W. A., Alghamdi, M., et al. (2018) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_159_18 · Cited by 14
“AIH with primary biliary cholangitis: The prevalence of overlap between the features of PBC and AIH is estimated to be 7–10% in patients with AIH.[27,74] Although there is no standardized approach to diagnose such overlap, the “Paris criteria” has been proposed to serve as a tool to diagnose AIH–PBC overlap.”
MethodTakamura, M., Matsuda, Y., Kimura, N., Takatsuna, M., Setsu, T., Tsuchiya, A., Osaki, A., Waguri, N., Yanagi, M., Takahashi, T., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13586 · Cited by 14
The management of autoimmunity in patients with cholestatic liver diseases
Ali, A. H., Carey, E. J., & Lindor, K. D. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1095088 · Cited by 15
“PSC–AIH overlap has been described mainly in children [29,33].”
BackgroundMethodInfluentialAbe, K., Takahashi, A., Nozawa, Y., Imaizumi, H., Hayashi, M., Okai, K., Kanno, Y., Watanabe, H., & Ohira, H. (2014) · Medical Molecular Morphology · doi:10.1007/s00795-014-0082-z · Cited by 14
“[1] based on whether patients met at least two of the three PBC criteria [serum ALP level”
BackgroundMethodInfluentialAutoimmune hepatitis, cryoglobulinaemia and untreated coeliac disease
Biecker, E., Stieger, M., Zimmermann, A., & Reichen, J. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200304000-00015 · Cited by 14
New autoantibodies and autoantigens in autoimmune hepatitis
Bianchi, F. B., Muratori, P., & Muratori, L. (2002) · Clinics in Liver Disease · doi:10.1016/s1089-3261(02)00027-2 · Cited by 14
Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination
Lee, S. K., Kwon, J. H., Yoon, N., Lee, S. H., & Sung, P. S. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.029 · Cited by 14
Laboratory Tests in Liver Disease
Vuppalanchi, R., & Chalasani, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-42873-6.00003-2 · Cited by 16
Gatselis, N., Zachou, K., Montaño‐Loza, A. J., Cançado, E. L. R., Arinaga‐Hino, T., Muratori, P., Efe, C., Floreani, A., Invernizzi, P., Takahashi, A., et al. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.06.001 · Cited by 15
Primary Biliary Cholangitis: A Brief Overview
Louie, J. S., Grandhe, S., Matsukuma, K. E., & Bowlus, C. L. (2020) · Clinical Liver Disease · doi:10.1002/cld.867 · Cited by 15
Mawardi, M., Alalwan, A. M., Fallatah, H. I., Abaalkhail, F. A., Hasosah, M. Y., Shagrani, M. A., Alghamdi, M., & Alghamdi, A. (2021) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_112_21 · Cited by 14
“[112‐115] The Paris criteria in particular were promulgated in 1998 with higher specificity (97%) and sensitivity (92%), for overlap syndrome diagnosis.[112] Furthermore, these are the most commonly utilized criteria which are recognized by AASLD and EASL to establish the overlap syndrome diagnosis in the presence of…”
MethodZhao, D., Yan, H., Liao, H.-Y., Liu, Y., Han, Y., Zhang, H., Zhang, W.-M., Huang, C., Liu, X., Lou, J.-L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1098076 · Cited by 17
Autoimmune Hepatitis: From Evolution to Current Status—A Pathologist’s Perspective
Sakhuja, P., & Goyal, S. (2024) · Diagnostics · doi:10.3390/diagnostics14020210 · Cited by 13
“Diagnosis of AIH with concurrent steatohepatitis (SH) of alcoholic or non-alcoholic etiology can be challenging.”
BackgroundDiagnóstico y tratamiento de los síndromes de sobreposición de hepatitis autoinmune
Aguilar-Nájera, O., Velasco-Zamora, J. A., & Torre, A. (2015) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2015.04.001 · Cited by 18
Weinmann, A., Sattler, T., Unold, H.-P., Grambihler, A., Teufel, A., Koch, S., Schuchmann, M., Biesterfeld, S., Wörns, M., Galle, P. R., et al. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000176 · Cited by 16
“Patient population Age at diagnosis (y) 52 (12-87) 55 (26-71) ( 7; 5) N.”
Casas, O. Y. M., Díaz-Ramírez, G. S., Marín, J. I., Santos, O. M., Maya, O. G. M., Gómez, J. R. M., & Restrepo, J. C. (2018) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2018.11.006 · Cited by 16
Watanabe, S. (2001) · Hepatology Research · doi:10.1016/s1386-6346(00)00083-8 · Cited by 15
Liu, S., Peng, C., Xia, S., Li, C., Dai, X., Liu, X., Zhang, M., Li, X., & Tang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1504066 · Cited by 14
The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine
Men, X., Liu, Y., Zhao, H., Xie, B., Guo, C., Leung, P. S. C., Timilsina, S., Gershwin, M. E., Shang, Y., & Han, Y. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09074-x · Cited by 15
“The endorsed Paris criteria [167] suggest that the PBC-AIH overlap syndrome can be diagnosed when liver histology shows moderate-to-severe interface hepatitis with at least one of the two diagnostic standards of AIH being satisfied simultaneously for PBC patients: (1) serum ALT ≥ 5 × ULN and (2)…”
InfluentialOptimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis
Zhu, G., Huang, S., Huang, G., Wang, L., Lin, Y.-Q., Wu, Y.-M., Shi, K., Wang, J., Zhou, Z., Braddock, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4528 · Cited by 13
“Few AEs were reported, which included osteoporosis, bleeding, aggravated itching, and diarrhea in only two included RCTs [26, 29] associated with COT plus UDCA.”
Jung, H. E., Jang, J. Y., Jeong, S. W., Kim, J. N., Jang, H. Y., Cho, Y. J., Woo, S. A., Lee, S. H., Kim, S. G., Cha, S., et al. (2012) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2012.18.4.375 · Cited by 12
Proposed therapies in primary biliary cholangitis
Floreani, A., Sun, Y. H., Zou, Z. S., Li, B., Cazzagon, N., Bowlus, C. L., & Gershwin, M. E. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1121810 · Cited by 14
Washington, M. K., & Manns, M. P. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00009-x · Cited by 12
Activation of Liver X Receptor α Sensitizes Mice to T‐Cell Mediated Hepatitis
Gao, L., Li, B., Wang, J., Shen, D., Yang, M., Sun, R., Tung, H., Xu, M., Ren, S., Zhang, M., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1584 · Cited by 12
“(16) Subjects diagnosed with primary biliary cholangitis–AIH overlap syndrome according to the Paris criteria(17) were excluded.”
BackgroundKayaçetin, E., Köklü, S., & Temuçin, T. K. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2003.09.023 · Cited by 12
“They have emphasized on the higher success of UDCA plus immunosuppression therapy compared to either therapy alone [10].”
BackgroundInfluentialThe role of the pathologist in diagnosing and grading biliary diseases
Nakanuma, Y., & Harada, K. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.01.018 · Cited by 12
Saito, H., Rai, T., Takahashi, A., Kanno, Y., Monoe, K., Irisawa, A., & Ohira, H. (2006) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.52.71 · Cited by 12
Diagnostic Criteria for Autoimmune Hepatitis: Scores and More
Lohse, A. W. (2015) · Digestive Diseases · doi:10.1159/000440709 · Cited by 12
Hepatic granulomas: a 17‐year single tertiary centre experience
Gaspar, R., Andrade, P., Silva, M., Peixoto, A., Lopes, J., Carneiro, F., Liberal, R., & Macedo, G. (2018) · Histopathology · doi:10.1111/his.13521 · Cited by 12
“Twelve of 48 patients with PBC had biochemical, serological and histological features of AIH, and were therefore diagnosed with PBC/ AIH overlap syndrome.(17) More interestingly, however, was the finding of hepatic granulomas in 11 patients with typical AIH.”
BackgroundMethodIdentification of clinical risk factors for histological progression of primary biliary cholangitis
Fujinaga, Y., Namisaki, T., Moriya, K., Kitade, M., Kawaratani, H., Shimozato, N., Kaji, K., Takaya, H., Sawada, Y., Seki, K., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13355 · Cited by 13
Sripongpun, P., Pongpaibul, A., & Charatcharoenwitthaya, P. (2021) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000701 · Cited by 12
Zhao, D., Liao, H.-Y., Liu, Y., Zhao, Y., Feng, X., & Yan, H. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1661-7 · Cited by 13
“Although elevated serum IgG was one of the diagnostic criteria for AIH, none of the patients in the study met the diagnostic criteria for PBC-AIH overlap syndrome, which required that at least two of three accepted criteria for PBC and AIH, respectively, should be present [11, 35 ].”
BackgroundNamisaki, T., Moriya, K., Kitade, M., Kawaratani, H., Takeda, K., Okura, Y., Takaya, H., Nishimura, N., Seki, K., Kaji, K., et al. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000765 · Cited by 14
Casas, O. Y. M., Díaz-Ramírez, G. S., Marín, J. I., Santos, O. M., Maya, O. G. M., Gómez, J. R. M., & Restrepo, J. C. (2018) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2018.05.019 · Cited by 14
WU, C.-H., WANG, Q.-H., TIAN, G.-S., XU, X.-Y., YU, Y.-Y., & WANG, G.-Q. (2006) · Chinese Medical Journal · doi:10.1097/00029330-200602010-00013 · Cited by 12
Lazaridis, K. N., & Lindor, K. D. (1999) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-999-0051-0 · Cited by 12
Noninvasive diagnosis of AIH/PBC overlap syndrome based on prediction models
Wang, K., Li, Y., Pan, J., He, H., Zhao, Z., Guo, Y., & Zhang, X. (2022) · Open Medicine · doi:10.1515/med-2022-0526 · Cited by 12
“unrecognized cause of resistance to ursodeoxycholic acid in patients with PBC [6].”
BackgroundRisk Stratification in Primary Biliary Cholangitis
Martini, F., Balducci, D., Mancinelli, M., Buzzanca, V., Fracchia, E., Tarantino, G., Benedetti, A., Marzioni, M., & Maroni, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175713 · Cited by 14
Yang, F., Zhou, L., Shen, Y., Wang, X., Fan, X., & Yang, L. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05029-6 · Cited by 11
“The majority of investigators have opted for a first-line treatment regimen that combines ursodeoxycholic acid (UDCA) and corticosteroids, with or without azathioprine (AZA) [10–17].”
BackgroundMethodInfluentialOverlap Syndromes of Autoimmune Hepatitis: An Open Question
Durazzo, M., Premoli, A., Paschetta, E., Belci, P., Spandre, M., & Bo, S. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2378-y · Cited by 11
“Although partial or complete remission of AIH have been reported after giving UDCA (13–15 mg/kg/die) [22, 23], many patients required combination therapy (UDCA plus steroid/immunosuppressor) in order to obtain a complete biochemical response [9].”
InfluentialPrevalence and Risk Factors of Diabetes Mellitus in Patients with Autoimmune Hepatitis
Matsumoto, N., Ogawa, M., Matsuoka, S., & Moriyama, M. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.4957 · Cited by 11
“AIH-primary biliary cirrhosis overlap syndrome was diagnosed based on previously reported criteria (24).”
The utility of repeat liver biopsy in autoimmune hepatitis: a series of 20 consecutive cases
Putra, J., Toor, A., & Suriawinata, A. A. (2016) · Pathology · doi:10.1016/j.pathol.2016.05.001 · Cited by 11
Current Treatment Options for Primary Biliary Cholangitis
Wong, K. A., Bahar, R., Liu, C. H., & Bowlus, C. L. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.003 · Cited by 11
Li, Z., Liu, Y., Yang, F., Pang, J., Wu, Y., Chong, Y., & Li, X. (2020) · BioMed Research International · doi:10.1155/2020/1934541 · Cited by 12
Calcineurin Inhibitors in the Treatment of Adult Autoimmune Hepatitis: A Systematic Review
Baven-Pronk, M., Hew, J. M., Biewenga, M., Tushuizen, M. E., van den Berg, A. P., Bouma, G., Brouwer, J. T., van Hoek, B., & Dutch Autoimmune Hepatitis Study Group (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00535 · Cited by 12
Czaja, A. J. (2014) · Clinical Liver Disease · doi:10.1002/cld.294 · Cited by 11
“This regimen has significantly improved laboratory findings, and it has prevented progressive hepatic fibrosis.(5) Combination therapy has also been superior to FIGURE 1 Porous diagnostic boundaries and commonly shared features of AIH, PBC, and PSC.”
BackgroundKowalec, K., Yoshida, E. M., Traboulsee, A. L., Carleton, B., & Tremlett, H. L. (2012) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2012.07.004 · Cited by 11
“In the absence of a liver biopsy, which could not be justified on clinical grounds, or any remarkable elevations in ALP, the accepted criteria of PBC-autoimmune hepatitis overlap syndrome are not fulfilled (Chazouilleres et al., 1998),”
BackgroundGuadalupi, G., Contini, C., Iavarone, F., Castagnola, M., Messana, I., Faa, G., Onali, S., Chessa, L., Vitorino, R. M. P., Amado, F. M. L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512207 · Cited by 11
“The most common AIH–PBC overlap syndrome [7] can be diagnosed using the Paris criteria, while so far there are no standardized diagnostic criteria for the other types of overlap syndromes [8].”
BackgroundDiagnosis of Autoimmune Hepatitis
Flikshteyn, B., Amer, K., Tafesh, Z., & Pyrsopoulos, N. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.06.004 · Cited by 14
Koyamada, R., Higuchi, T., Kitada, A., Nakagawa, T., Ikeya, T., Okada, S., & Fujita, Y. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.4405 · Cited by 10
“PBC-AIH overlap syndrome is a simultaneous or consecutive association of PBC and AIH (9, 10) and, like PBC and AIH, is frequently associated with extrahepatic autoimmune disorders (11); however, the frequency of antiplatelet antibodies has not yet been studied despite occasional case reports of the association with im…”
BackgroundPiga, M., Vacca, A., Porru, G., Garau, P., Cauli, A., & Mathieu, A. (2011) · Lupus · doi:10.1177/0961203311411352 · Cited by 10
Update on Emerging Treatment Options for Primary Biliary Cholangitis
Aguilar, M. T., & Chascsa, D. M. H. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s205431 · Cited by 11
Nielsen, K. R., Midjord, J., Johannesen, H. L., & Grønbæk, H. (2023) · International Journal of Circumpolar Health · doi:10.1080/22423982.2023.2221368 · Cited by 10
“Some patients display the characteristics of both PBC and AIH based on clinical, biochemical, immunological, or histological features at different stages during their disease.”
BackgroundInfluentialLudz, C., Stirnimann, G., Semela, D., Mertens, J. C., Kremer, A. E., Sinnreich, M. F., Sokollik, C., Bernsmeier, C., Bresson‐Hadni, S., McLin, V. A., et al. (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40102 · Cited by 10
Hépatites auto-immunes : actualités diagnostiques et thérapeutiques
Corpechot, C., & Chazouillères, O. (2010) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2009.05.015 · Cited by 10
Self-citationEfe, C., Özaslan, E., & Pürnak, T. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.06.003 · Cited by 11
Treatment of Primary Biliary Cholangitis
Liu, C.-H., & Bowlus, C. L. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.012 · Cited by 9
Overlap syndrome: A real syndrome?
Haldar, D., & Hirschfield, G. M. (2014) · Clinical Liver Disease · doi:10.1002/cld.317 · Cited by 9
“The classification proposed by Chazouille ‡ res et al.(11) remains the most commonly used tool for diagnosing AIH/PBC overlap, yet the reported prevalence in the literature of AIH occurring in the context of PBC (depending on the criteria used) varies between 2.”
MethodYilmaz, K., Haeberle, S., Kim, Y. O., Fritzler, M. J., Weng, S., Goeppert, B. F., Raker, V., Steinbrink, K., Schuppan, D., Enk, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1253649 · Cited by 9
Metadata
- Authors
- Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R.
- Affiliations
- Assistance Publique – Hôpitaux de Paris (FR)
- Corresponding author
- Chazouillères, Olivier
- Venue
- Hepatology
- Published
- 1998-08
- Volume
- 28
- Issue
- 2
- Pages
- 296-301
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2056147648
- Semantic Scholar
- e5878dda2aeaf614ad753e5c66ea3a752edfb605
- Cited by
- 746
- References
- 34
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 37 · 2023: 37 · 2022: 32 · 2021: 31 · 2020: 31 · 2019: 27 · 2018: 38 · 2017: 31 · 2016: 28 · 2015: 36 · 2014: 32 · 2013: 32 · 2012: 33
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6240 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, autoimmune hepatitis, overlap syndrome, ursodeoxycholic acid, corticosteroids, combination therapy, treatment resistance, anti-smooth muscle antibodies, antimitochondrial antibodies, cholestasis, liver fibrosis, IgG, anti-amyloid antibodies, remission, disease flares, bile duct lesions
- MeSH terms
- Adrenal Cortex Hormones, Adult, Aged, Cholagogues and Choleretics, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Liver Cirrhosis, Biliary, Male, Middle Aged, Syndrome, Ursodeoxycholic Acid, Treatment Outcome, Hepatitis, Autoimmune
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.